D’Haens G, et al. - A prospective, randomized trial was designed to determine whether therapeutic drug monitoring to maintain serum levels of infliximab above 3 μg/mL produced higher rates of clinical and endoscopic remission than adapting dose based only on symptoms. The researchers found that compared to increasing dose based on symptoms alone, increasing dose of infliximab based on a combination of symptoms, biomarkers, and serum drug concentrations did not lead to corticosteroid-free clinical remission in a larger proportion of patients.